MA29817B1 - Derives de prolinamide utilises comme modulateurs du canal sodium - Google Patents

Derives de prolinamide utilises comme modulateurs du canal sodium

Info

Publication number
MA29817B1
MA29817B1 MA30797A MA30797A MA29817B1 MA 29817 B1 MA29817 B1 MA 29817B1 MA 30797 A MA30797 A MA 30797A MA 30797 A MA30797 A MA 30797A MA 29817 B1 MA29817 B1 MA 29817B1
Authority
MA
Morocco
Prior art keywords
modulators
sodium channel
prolinamide derivatives
prolinamide
derivatives
Prior art date
Application number
MA30797A
Other languages
English (en)
Inventor
Giuseppe Alvaro
Markus Bergauer
Riccardo Giovannini
Roberto Profeta
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520581A external-priority patent/GB0520581D0/en
Priority claimed from GB0523045A external-priority patent/GB0523045D0/en
Priority claimed from GB0603900A external-priority patent/GB0603900D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA29817B1 publication Critical patent/MA29817B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L'INVENTION DÉCRIT UN COMPOSÉ DE FORMULE (I), UN DES SES SOLVATES, SELS OU PROMÉDICAMENTS UTILES DANS LE TRAITEMENT DE MALADIES ET DE PATHOLOGIES MÉDIÉES PAR LA MODULATION DE CANAUX SODIUM SENSIBLES AU VOLTAGE.
MA30797A 2005-10-10 2008-03-31 Derives de prolinamide utilises comme modulateurs du canal sodium MA29817B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0523045A GB0523045D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0603900A GB0603900D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds

Publications (1)

Publication Number Publication Date
MA29817B1 true MA29817B1 (fr) 2008-09-01

Family

ID=37546777

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30797A MA29817B1 (fr) 2005-10-10 2008-03-31 Derives de prolinamide utilises comme modulateurs du canal sodium

Country Status (20)

Country Link
US (2) US7655693B2 (fr)
EP (1) EP1934177B8 (fr)
JP (1) JP5139305B2 (fr)
KR (1) KR101282464B1 (fr)
AR (1) AR056575A1 (fr)
AT (1) ATE556049T1 (fr)
AU (1) AU2006301470B2 (fr)
BR (1) BRPI0616944B8 (fr)
CA (1) CA2625642C (fr)
CR (1) CR9898A (fr)
EA (1) EA015736B1 (fr)
ES (1) ES2387405T3 (fr)
IL (1) IL192627A0 (fr)
MA (1) MA29817B1 (fr)
NO (1) NO20082145L (fr)
NZ (1) NZ567051A (fr)
PE (1) PE20070592A1 (fr)
PL (1) PL1934177T3 (fr)
TW (1) TW200730494A (fr)
WO (1) WO2007042239A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
US7855218B2 (en) * 2005-10-10 2010-12-21 Convergence Pharmaceuticals Limited Compounds
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
WO2011015537A1 (fr) 2009-08-05 2011-02-10 Glaxo Group Limited Co-thérapie pour le traitement de l'épilepsie et des troubles associés
JP5855000B2 (ja) * 2009-09-14 2016-02-09 クオンベルゲンセ プハルマセウトイカルス リミテッド α−カルボキサミド誘導体の製造方法
CA2828456C (fr) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. Inhibiteurs n-benzyl-amino-carboxamide du canal sodique
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
US9676757B2 (en) 2014-02-27 2017-06-13 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
ES2912881T3 (es) * 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
CN110167553A (zh) * 2016-11-02 2019-08-23 生物基因麻省公司 新颖的剂量方案
MX2019013758A (es) * 2017-05-19 2020-07-20 Biogen Ma Inc Formas cristalinas novedosas.
KR20200061381A (ko) * 2017-10-05 2020-06-02 바이오젠 인크. 알파-카르복스아미드 피롤리딘 유도체를 제조하기 위한 공정
AU2018347349A1 (en) 2017-10-10 2020-04-23 Biogen Inc. Process for preparing spiro derivatives
AU2019255519A1 (en) * 2018-04-16 2020-10-01 Biogen Ma Inc. Methods of treating neuropathic pain
US20220162164A1 (en) * 2019-04-10 2022-05-26 Biongen Inc. Processes for preparing alpha-carboxamide pyrrolidine derivatives
BR112021020345A2 (pt) * 2019-04-10 2021-12-14 Biogen Ma Inc Processo para preparação de derivados de alfacarboxamida pirrolidina
WO2021154631A1 (fr) * 2020-01-30 2021-08-05 Javed Mohammad Polythérapies pour le traitement de troubles du système nerveux central

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6136131A (en) * 1998-06-02 2000-10-24 Instrument Specialties Company, Inc. Method of shielding and obtaining access to a component on a printed circuit board
BR0009322A (pt) 1999-03-26 2002-04-30 Euro Celtique Sa Pirazóis, imidazóis, oxazóis, tiazóis e pirróis substituìdos com arila e o uso dos mesmos
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
PA8583001A1 (es) 2002-09-20 2004-04-23 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil eter como inhibidores de mao-b
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
JP2006522130A (ja) 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール
US20070060584A1 (en) * 2003-04-18 2007-03-15 Chakravarty Prasun K Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2005000309A2 (fr) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Composes chimiques
EP1524265A1 (fr) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Dérivés de prolinamide en tant que bloqueurs du canal sodium et/ou calcium ou inhibiteurs sélectifs de MAO-B
WO2005100334A1 (fr) 2004-04-14 2005-10-27 Pfizer Products Inc. Inhibiteurs de dipeptidyl peptidase-iv
JP2008540438A (ja) 2005-05-04 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なピリジン
WO2006119451A1 (fr) 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyrimidines et pyrazines utilisees comme modulateurs des canaux ioniques
WO2006124865A2 (fr) 2005-05-19 2006-11-23 Vertex Pharmaceuticals Incorporated Biaryles utiles en tant que modulateurs des canaux ioniques
DE602006021323D1 (de) 2005-09-09 2011-05-26 Glaxosmithkline Llc Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
US7855218B2 (en) 2005-10-10 2010-12-21 Convergence Pharmaceuticals Limited Compounds
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
EP2129381A1 (fr) 2007-01-24 2009-12-09 Glaxo Group Limited Nouvelles compositions pharmaceutiques
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
ATE556049T1 (de) 2012-05-15
EA200801054A1 (ru) 2008-08-29
WO2007042239A1 (fr) 2007-04-19
BRPI0616944B1 (pt) 2020-04-14
IL192627A0 (en) 2011-08-01
BRPI0616944A2 (pt) 2011-07-05
US8153681B2 (en) 2012-04-10
CA2625642C (fr) 2013-12-24
NZ567051A (en) 2011-03-31
US7655693B2 (en) 2010-02-02
TW200730494A (en) 2007-08-16
KR20080059296A (ko) 2008-06-26
EA015736B1 (ru) 2011-10-31
BRPI0616944B8 (pt) 2021-05-25
PE20070592A1 (es) 2007-06-23
NO20082145L (no) 2008-05-07
CA2625642A1 (fr) 2007-04-19
CR9898A (es) 2008-07-29
AU2006301470B2 (en) 2012-06-14
EP1934177B8 (fr) 2012-09-05
JP2009511519A (ja) 2009-03-19
US20100105754A1 (en) 2010-04-29
EP1934177B1 (fr) 2012-05-02
PL1934177T3 (pl) 2013-03-29
ES2387405T3 (es) 2012-09-21
AR056575A1 (es) 2007-10-10
KR101282464B1 (ko) 2013-07-04
AU2006301470A1 (en) 2007-04-19
EP1934177A1 (fr) 2008-06-25
US20080280969A1 (en) 2008-11-13
JP5139305B2 (ja) 2013-02-06

Similar Documents

Publication Publication Date Title
MA29817B1 (fr) Derives de prolinamide utilises comme modulateurs du canal sodium
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
EA200802213A1 (ru) Способы лечения заболеваний крови
BRPI0410711A (pt) novos compostos
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
ATE525372T1 (de) Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
TW200728258A (en) Novel compounds
MX2009002002A (es) Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
BRPI0719590A2 (pt) Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA29870B1 (fr) Nouveaux dérivés de 1-azabicycloalkyles dans le traitement de troubles psychotiques et neurodégénératifs
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
NO20063064L (no) Ny anvendelse av peptidforbindelser for behandling av sentralneurotisk smerte
MA31564B1 (fr) Inhibition par arni de l'expression du canal alpha-enac
EA201290267A1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
MXPA05009535A (es) Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
MA28562B1 (fr) 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
MA27111A1 (fr) Derives de benzofurane et de benzothiophene utilises dans le traitement de troubles hyperproliferatifs
TR201818771T4 (tr) Bilişsel Bozuklukların Tedavisinde Kullanıma Yönelik Bileşikler
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels